A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis

Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab Versus Placebo in Patients With Systemic Sclerosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Systemic scleroderma
  • Focus Registrational; Therapeutic Use
  • Acronyms focuSSced
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 25 Jul 2017 Planned End Date changed from 31 Mar 2019 to 12 Feb 2019.
    • 25 Jul 2017 Planned primary completion date changed from 1 May 2019 to 16 Jan 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top